Bayer Push To Lead OTC Space Relies On Distribution, Emerging Markets
This article was originally published in PharmAsia News
Bayer expands its distribution, invests in emerging markets and innovation and acquires strategic bolt-ons in an attempt to replace Johnson & Johnson as the largest global OTC business, executives say. Growth areas include gastrointestinal and cough/cold products, but not Rx-to-OTC switch.
You may also be interested in...
Bayer buys herbal firm; NBTY notes bright spots, hires international leader; Neptune prepares to rebuild; P&G suit targets CAO’s tooth whiteners; CSPI supports restricting St. John’s wort; Coppertone schools parents; Hillary Clinton will speak at NACDS Total Store Expo.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.